登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>CXCR4 >CX4-H5219

Human CXCR4 / CD184 Full Length Protein (VLP)

分子别名(Synonym)

CXCR4,CD184,Fusin,D2S201E,FB22,HM89,HSY3RR,LAP3,LCR1,LESTR,NPY3R,NPYR,NPYRL,NPYY3R,WHIM

表达区间及表达系统(Source)

Human CXCR4 Full Length Protein-VLP (CX4-H5219) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ser 352 (Accession # P61073-1).

Predicted N-terminus: His

蛋白结构(Molecular Characterization)

The protein has a calculated MW of 41.6 kDa | 56.1 kDa.

Virus-like particles(VLPs) are formed by self-assembly of envelop/capsid proteins from viruses. Membrane Proteins can be constituted in-situ with VLPs produced from HEK293 cell cultures. These VLPs concentrate conformationally intact membrane proteins directly on the cell surface and produce soluble, high-concentration proteins perfect for immunization and antibody screening.

The VLPs provide the display of properly folded membrane proteins in their native cellular membrane in a compact size of 100~300 nm diameter (similar to the size of most viruses) making it optimal targets for dendritic cells in vivo and surface attachment for phage display.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

制剂(Formulation)

The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

运输(Shipping)

This product is supplied and shipped with dry ice, please inquire the shipping cost.

存储(Storage)

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. The product MUST be stored at -70°C or lower upon receipt;
  2. -70°C for 12 months under sterile conditions.
*The isotype control of empty/mock VLP (Cat. No. VLP-N5213) is sold separately and not included in protein, you can follow this link for product information.
 

活性(Bioactivity)-ELISA

CXCR4 ELISA

Immobilized Human CXCR4 Full Length Protein-VLP (Cat. No. CX4-H5219) at 5 μg/mL (100 μL/well) can bind Human ulocuplumab, Human IgG4 with a linear range of 1-31 ng/mL (QC tested).

Protocol

 

均一性(Identity)-DLS

CXCR4 DLS

The mean peak Radius of VLP is 55-75 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

 

背景(Background)

C-X-C chemokine receptor type 4 is also known as fusin or CD184 (cluster of differentiation 184), CXCR4, CD184, D2S201E, FB22, HM89, HSY3RR, LAP3, LCR1, LESTR, NPY3R, NPYR, NPYRL, NPYY3R or WHIM. CXCR-4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1 also called CXCL12), a molecule endowed with potent chemotactic activity for lymphocytes. This receptor is one of several chemokine receptors that HIV isolates can use to infect CD4+ T cells. HIV isolates that use CXCR4 are traditionally known as T-cell tropic isolates. Typically, these viruses are found late in infection. It is unclear as to whether the emergence of CXCR4 using HIV is a consequence or a cause of immunodeficiency.CXCR4 is upregulated during the implantation window in natural and hormone replacement therapy cycles in the endometrium, producing, in presence of a human blastocyst, a surface polarization of the CXCR4 receptors suggesting that this receptor is implicated in the adhesion phase of human implantation. SDF-1 and CXCR4 were believed to be a relatively "monogamous" ligand-receptor pair (other chemokines tend to use several different chemokine receptors in a fairly "promiscuous" manner). Recent evidence demonstrates ubiquitin is also a natural ligand of CXCR4. Chronic exposure to THC increased T lymphocyte CXCR4 expression on both CD4+ and CD8+ T lymphocytes. Drugs that block the CXCR4 receptor appear to be capable of "mobilizing" hematopoietic stem cells into the bloodstream as peripheral blood stem cells.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
CXCR4靶点信息
英文全称:C-X-C motif chemokine receptor 4
中文全称:C-X-C基序趋化因子受体4
种类:Homo sapiens
上市药物数量:2详情
临床药物数量:25详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定